MAPT and Alzheimer disease: The positive association of CSF biomarkers, including Aβ1-42, t-tau, and p-tau, with AD means that CSF biomarkers can be used to provide a higher degree of sensitivity and specificity compared with clinical diagnosis alone (See Box 1 and Box 2) (14, 15).